NCT02878083 - Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

January 1, 2021

Conditions

ULCERATIVE COLITIS

Interventions

DRUG

VEDOLIZUMAB

Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only

DRUG

ADALIMUMAB

For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28

Trial Locations (4)

Chu Angers, Angers

Chd Vendee, La Roche-sur-Yon

Chu Nantes, Nantes

Chu Rennes, Rennes